Table 1.
Clinical Trials targeting IL-10.
| Cytokine | Drug | Sponsor | Description | Indication | Clinical trial |
|---|---|---|---|---|---|
| IL-10 | Prevascar | Renovo | Recombinant human IL-10 | Wound healing | Phase 2 NCT00984646 |
| AS101 | BioMAS Ltd | Tellurium based small compound with immune-modulating characteristics attributed to direct inhibition of IL-10 | Treatment of thrombo-cytopenia in solid tumor patients | Phase 2 NCT00926354 |
|
| T-allo10 | Stanford University | Donor-derived CD4+ T cells which contain a high proportion of host alloantigen specific Tr1 cells | Therapy to prevent GvHD and induce graft tolerance in hematopoietic stem cell transplant | Phase 1 NCT03198234 |
|
| Pegilodecakin (LY3500518 or AM0010) | Eli Lilly and Company | PEGylated recombinant human IL-10 | Pancreatic cancer | Phase 3 NCT02923921 |